Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-Blind, Equivalence Study of the Efficacy of Darbepoetin Alfa Manufactured by Serum Free Bioreactor Technology and Darbepoetin Alfa Manufactured by Roller-Bottle Technology for the Treatment of Anemia in Patients With Chronic Kidney Disease Receiving Hemodialysis

NCT00121602 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00121602
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00121602 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-Blind, Equivalence Study of the Efficacy of Darbepoetin Alfa Manufactured by Serum Free Bioreactor Technology and Darbepoetin Alfa Manufactured by Roller-Bottle Technology for the Treatment of Anemia in Patients With Chronic Kidney Disease Receiving Hemodialysis
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2005
Completion date
October 31, 2006
Enrollment
446 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, kidney disease